Skip to main content

Elan Pharmaceuticals Joins GeneGo's MetaTox Consortium

NEW YORK (GenomeWeb News) - Elan Pharmaceuticals has joined the MetaTox Consortium, a group spearheaded by informatics firm GeneGo that aims to address the reasons behind the failure of investigational drugs in clinical trials.
 
GeneGo said the consortium includes members from industry and the US Food and Drug Administration and will focus on using systems biology tools and informatics to assess the safety of small molecule compounds and therapeutics.
 
The group will focus its efforts on developing predictive models, increasing toxicity knowledge, and developing data analysis software for use in systems biology, GeneGo said.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.